MAPK1 and breast cancer: Experiments with MEK1 inhibitors have shown that ERK activity correlates with cell proliferation (Seddighzadeh et al, 1999) and motility (Krueger et al, 2001) in breast cancer cell lines, but does not influence cell invasion.